Perturbation of the retinoblastoma (Rb) pathway, a key modulator of cell cycle advancement, has prompted the evolution of CDK4/6 inhibitors as a treatment strategy for breast carcinoma. This evidence concerns the gene CDK4 and breast carcinoma.